184 related articles for article (PubMed ID: 8192447)
1. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B.
Wasan KM; Rosenblum MG; Cheung L; Lopez-Berestein G
Antimicrob Agents Chemother; 1994 Feb; 38(2):223-7. PubMed ID: 8192447
[TBL] [Abstract][Full Text] [Related]
2. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein.
Wasan KM; Morton RE; Rosenblum MG; Lopez-Berestein G
J Pharm Sci; 1994 Jul; 83(7):1006-10. PubMed ID: 7965656
[TBL] [Abstract][Full Text] [Related]
3. Modification of amphotericin B's therapeutic index by increasing its association with serum high-density lipoproteins.
Wasan KM; Lopez-Berestein G
Ann N Y Acad Sci; 1994 Aug; 730():93-106. PubMed ID: 8080218
[TBL] [Abstract][Full Text] [Related]
4. The interaction of liposomal amphotericin B and serum lipoproteins within the biological milieu.
Wasan KM; Lopez-Berestein G
J Drug Target; 1994; 2(5):373-80. PubMed ID: 7704481
[TBL] [Abstract][Full Text] [Related]
5. In vitro cytotoxicity of two novel oral formulations of Amphotericin B (iCo-009 and iCo-010) against Candida albicans, human monocytic and kidney cell lines.
Leon CG; Lee J; Bartlett K; Gershkovich P; Wasan EK; Zhao J; Clement JG; Wasan KM
Lipids Health Dis; 2011 Aug; 10():144. PubMed ID: 21854638
[TBL] [Abstract][Full Text] [Related]
6. Preferential distribution of amphotericin B lipid complex into human HDL3 is a consequence of high density lipoprotein coat lipid content.
Kennedy AL; Wasan KM
J Pharm Sci; 1999 Nov; 88(11):1149-55. PubMed ID: 10564063
[TBL] [Abstract][Full Text] [Related]
7. Unidirectional inhibition of lipid transfer protein I-mediated transfer of cholesteryl esters between high-density and low-density lipoproteins by amphotericin B lipid complex.
Sivak O; Lau B; Patankar N; Wasan KM
Pharm Res; 2004 Dec; 21(12):2336-9. PubMed ID: 15648266
[TBL] [Abstract][Full Text] [Related]
8. Diversity of lipid-based polyene formulations and their behavior in biological systems.
Wasan KM; Lopez-Berestein G
Eur J Clin Microbiol Infect Dis; 1997 Jan; 16(1):81-92. PubMed ID: 9063678
[TBL] [Abstract][Full Text] [Related]
9. Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins.
Wasan KM; Brazeau GA; Keyhani A; Hayman AC; Lopez-Berestein G
Antimicrob Agents Chemother; 1993 Feb; 37(2):246-50. PubMed ID: 8452354
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies.
Wasan KM; Kennedy AL; Cassidy SM; Ramaswamy M; Holtorf L; Chou JW; Pritchard PH
Antimicrob Agents Chemother; 1998 Dec; 42(12):3146-52. PubMed ID: 9835506
[TBL] [Abstract][Full Text] [Related]
11. Role of phospholipid transfer protein on the plasma distribution of amphotericin B following the incubation of different amphotericin B formulations.
Patankar N; Wasan KM
Pharm Res; 2006 May; 23(5):1020-4. PubMed ID: 16715392
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of the proliferation of the Madin-Darby canine kidney (MDCK) epithelial cell line by high-density lipoproteins and their induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity.
Gospodarowicz D; Cohen DC; Massoglia SL
J Cell Physiol; 1983 Oct; 117(1):76-90. PubMed ID: 6352714
[TBL] [Abstract][Full Text] [Related]
13. Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects.
Lagrost L; Gandjini H; Athias A; Guyard-Dangremont V; Lallemant C; Gambert P
Arterioscler Thromb; 1993 Jun; 13(6):815-25. PubMed ID: 8499401
[TBL] [Abstract][Full Text] [Related]
14. Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulations.
Joly V; Bolard J; Saint-Julien L; Carbon C; Yeni P
Antimicrob Agents Chemother; 1992 Feb; 36(2):262-6. PubMed ID: 1605590
[TBL] [Abstract][Full Text] [Related]
15. Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans.
Wasan EK; Bartlett K; Gershkovich P; Sivak O; Banno B; Wong Z; Gagnon J; Gates B; Leon CG; Wasan KM
Int J Pharm; 2009 May; 372(1-2):76-84. PubMed ID: 19236839
[TBL] [Abstract][Full Text] [Related]
16. Analytical method development and comparability study for AmBisome® and generic Amphotericin B liposomal products.
Liu Y; Mei Z; Mei L; Tang J; Yuan W; Srinivasan S; Ackermann R; Schwendeman AS
Eur J Pharm Biopharm; 2020 Dec; 157():241-249. PubMed ID: 32980448
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis.
Wasan KM; Conklin JS
Antimicrob Agents Chemother; 1996 Aug; 40(8):1806-10. PubMed ID: 8843285
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antifungal activity and reduced toxicity of liposomal amphotericin B combined with gramicidin S or NF.
Hopfer RL; Mehta R; Lopez-Berestein G
Antimicrob Agents Chemother; 1987 Dec; 31(12):1978-81. PubMed ID: 2449867
[TBL] [Abstract][Full Text] [Related]
19. Effect of heat-treated amphotericin B on renal and fungal cytotoxicity.
Bartlett K; Yau E; Hartsel SC; Hamer A; Tsai G; Bizzotto D; Wasan KM
Antimicrob Agents Chemother; 2004 Jan; 48(1):333-6. PubMed ID: 14693561
[TBL] [Abstract][Full Text] [Related]
20. Role of humoral mediators in, and influence of a liposomal formulation on, acute amphotericin B nephrotoxicity.
Sabra R; Zeinoun N; Sharaf LH; Ghali R; Beshara G; Serhal H
Pharmacol Toxicol; 2001 Apr; 88(4):168-75. PubMed ID: 11322173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
